— Better urinary and erectile function results with high-intensity concentrated ultrasound
by Mike Bassett, Staff Writer, MedPage Today
May 4, 2024
SAN ANTONIO– A contrast of high-intensity concentrated ultrasound (HIFU) and extreme prostatectomy (RP) discovered that HIFU was non-inferior to surgical treatment as main treatment for localized prostate cancer, according to a French trial.
At a follow-up of 30 months, clients treated with HIFU had a substantially greater salvage treatment-free survival rate than clients who went through RP (89.8% vs 86.2%, HR 0.76, 95% CI 0.61-0.96, P=0.008), reported Pascal Rischmann, MD, PhD, of Toulouse Academic Hospital in Toulouse.
Outcomes were comparable when changed for age and other covariates at standard, consisting of BMI, American Society of Anesthesiologists physical status rating, Prostate volume, PSA level, and grade group (HR 0.71, 95% CI 0.52-0.97, P=0.03).
Clients treated with HIFU had much better practical outcomes relating to urinary continence and erectile function, Rischmann observed.
This is the very first potential research study comparing HIFU and RP as a main treatment for localized prostate cancer grade group 1 and 2, Rischmann stated throughout a plenary session at the American Urological Association yearly conference. “Salvage treatment-free survival after HIFU was not inferior compared to extreme prostatectomy.”
The HIFI research study was a non-inferiority, potential, non-randomized research study carried out in 46 centers throughout France from April 2015 through September 2019. The trial consisted of an overall of 3,328 clients, 1,967 of whom were treated with HIFU and 1,361 went through RP.
Clients were qualified for the research study if they had low- or intermediate-risk prostate cancer (PSA &